Proline oxidase, a p53-induced gene, targets COX-2/PGE2 signaling to induce apoptosis and inhibit tumor growth in colorectal cancers.
Proline oxidase (POX), a flavoenzyme localized at the inner mitochondrial membrane, catalyzes the first step of proline degradation by converting proline to pyrroline-5-carboxylate (P5C). POX is markedly elevated during p53-induced apoptosis and generates proline-dependent reactive oxygen species (ROS), specifically superoxide radicals, to induce apoptosis through both mitochondrial and death receptor pathways. These previous studies also showed suppression of the mitogen-activated protein kinase pathway leading us to broaden our exploration of proliferative signaling. In our current report, we used DLD-1 colorectal cancer cells stably transfected with the POX gene under the control of a tetracycline-inducible promoter and found that three pathways which cross talk with each other were downregulated by POX: the cyclooxygenase-2 (COX-2) pathway, the epidermal growth factor receptor (EGFR) pathway and the Wnt/beta-catenin pathway. First, POX markedly reduced COX-2 expression, suppressed the production of prostaglandin E2 (PGE(2)) and importantly, the growth inhibition by POX was partially reversed by treatment with PGE(2.) Phosphorylation of EGFR was decreased with POX expression and the addition of EGF partially reversed the POX-dependent downregulation of COX-2. Wnt/beta-catenin signaling was decreased by POX in that phosphorylation of glycogen synthase kinase-3beta (GSK-3beta) was decreased on the one hand and phosphorylation of beta-catenin was increased on the other. There changes led to decreased accumulation of beta-catenin and decreased beta-catenin/TCF/LEF-mediated transcription. Our newly described POX-mediated suppression of proliferative signaling together with the previously reported induction of apoptosis suggested that POX could function as a tumor suppressor. Indeed, in human colorectal tissue samples, immunohistochemically-monitored POX was dramatically decreased in tumors compared with normal counterparts. Thus, POX metabolism of substrate proline affects multiple signaling pathways, modulating both apoptosis and tumor growth, and could be an attractive target to metabolically control the cancer phenotypes.
Liu
Y
Y
1Basic Research Program, SAIC-Frederick, Inc., National Cancer Institute at Frederick, Frederick, MD 21702, USA.
Borchert
G L
GL
Surazynski
A
A
Phang
J M
JM
D017209:Apoptosis; D045744:Cell Line, Tumor; D015179:Colorectal Neoplasms / Q000201:enzymology* / Q000235:genetics; D051546:Cyclooxygenase 2 / Q000235:genetics / Q000378:metabolism*; D015232:Dinoprostone / Q000378:metabolism*; D015536:Down-Regulation; D066246:ErbB Receptors / Q000235:genetics / Q000378:metabolism; D015972:Gene Expression Regulation, Neoplastic; D038362:Glycogen Synthase Kinase 3 / Q000235:genetics / Q000378:metabolism; D000071679:Glycogen Synthase Kinase 3 beta; D006801:Humans; D024101:Mitochondrial Proteins / Q000096:biosynthesis* / Q000235:genetics; D010766:Phosphorylation; D011392:Proline / Q000235:genetics / Q000378:metabolism; D011394:Proline Oxidase / Q000096:biosynthesis* / Q000235:genetics; D017382:Reactive Oxygen Species / Q000378:metabolism; D015398:Signal Transduction; D014158:Transcription, Genetic; D016159:Tumor Suppressor Protein p53 / Q000235:genetics / Q000378:metabolism*; D051153:Wnt Proteins / Q000235:genetics / Q000378:metabolism; D051176:beta Catenin / Q000235:genetics / Q000378:metabolism
D024101:Mitochondrial Proteins; D017382:Reactive Oxygen Species; C495901:TP53 protein, human; D016159:Tumor Suppressor Protein p53; D051153:Wnt Proteins; D051176:beta Catenin; D011392:Proline; D051546:Cyclooxygenase 2; C496540:PTGS2 protein, human; D011394:Proline Oxidase; C512478:EGFR protein, human; D066246:ErbB Receptors; C000605506:GSK3B protein, human; D000071679:Glycogen Synthase Kinase 3 beta; D038362:Glycogen Synthase Kinase 3; D015232:Dinoprostone
J Biol Chem. 2004 Apr 30;279(18):18694-700
14976201
Arch Biochem Biophys. 1986 Jul;248(1):166-74
3729412
Oncogene. 2006 Sep 14;25(41):5640-7
16619034
J Biol Chem. 2005 Jul 15;280(28):26565-72
15899904
Dev Cell. 2006 Jun;10(6):687-8
16740470
J Biol Chem. 2006 Jan 27;281(4):2044-52
16303758
Cancer Res. 2005 Sep 15;65(18):8242-9
16166300
J Clin Invest. 1997 Sep 15;100(6):1325-9
9294096
Curr Pharm Des. 2004;10(6):635-46
14965326
Nat Rev Cancer. 2001 Oct;1(1):11-21
11900248
Cell. 1996 Oct 18;87(2):159-70
8861899
Acta Neuropathol. 2002 Apr;103(4):415-20
11904762
J Biol Chem. 2000 Apr 21;275(16):11750-7
10766797
J Biol Chem. 1988 Sep 15;263(26):13083-9
2458343
Hum Mol Genet. 1999 Dec;8(13):2359-68
10556283
Cell. 1996 Nov 29;87(5):803-9
8945508
J Biol Chem. 2004 Apr 2;279(14):14287-93
14742435
Trends Cell Biol. 2007 Jun;17(6):286-91
17481900
Clin Transl Oncol. 2006 Oct;8(10):711-6
17074669
Cancer Res. 1998 Feb 1;58(3):409-12
9458081
Carcinogenesis. 2005 Aug;26(8):1335-42
15817612
Am J Med Genet A. 2006 Apr 15;140(8):906-9
16532473
J Clin Oncol. 2005 Jan 10;23(2):254-66
15637389
Adv Anat Pathol. 2006 Sep;13(5):270-4
16998321
World J Gastroenterol. 2007 Jul 28;13(28):3784-91
17657831
Nat Rev Cancer. 2007 Feb;7(2):139-47
17218951
J Biol Chem. 2005 Aug 12;280(32):29346-54
15914462
Nature. 1997 Sep 18;389(6648):300-5
9305847
CA Cancer J Clin. 2005 Jan-Feb;55(1):10-30
15661684
Mol Biol Cell. 2005 Dec;16(12):5579-91
16195339
Cancer Res. 2001 Mar 1;61(5):1810-5
11280728
Science. 2005 Dec 2;310(5753):1504-10
16293724
J Biol Chem. 2003 Sep 12;278(37):35451-7
12824187
Cancer Res. 2003 Feb 1;63(3):728-34
12566320
Biochim Biophys Acta. 2000 Mar 27;1470(2):M69-78
10722929
Science. 2007 Nov 16;318(5853):1108-13
17932254
Int J Cancer. 2008 Mar 15;122(6):1435-40
17999410
J Biol Chem. 2003 Mar 14;278(11):9784-9
12514185